Keng-hsin Lan
Taipei, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Clinical impact of pharmacogenetic risk variants in a large chinese cohort.
Journal: Nature communications
Published: October 25, 2024
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas.
Journal: Alimentary pharmacology & therapeutics
Published: July 07, 2024
Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors.
Journal: The FEBS journal
Published: April 28, 2023
Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Journal: International journal of molecular sciences
Published: August 10, 2022
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma.
Journal: Therapeutic advances in medical oncology
Published: December 02, 2021
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
Journal: BMC infectious diseases
Published: March 16, 2021
(Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-β1/SMAD3 Pathway.
Journal: Cellular and molecular gastroenterology and hepatology
Published: December 17, 2020
Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir.
Journal: Journal of the Chinese Medical Association : JCMA
Published: December 04, 2020
Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: August 11, 2020
Last Updated: 09/26/2026